Search

Your search keyword '"Ortiz-Sanjuan, F"' showing total 35 results
Start Over Author "Ortiz-Sanjuan, F"
35 results on '"Ortiz-Sanjuan, F"'

1. AB1278 THE ROLE OF NLRP1 POLYMORPHISMS IN THE PATHOGENESIS OF GIANT CELL ARTERITIS

Author

Pulito-Cueto, V., primary, López-Mejías, R., additional, Loricera, J., additional, Sebastián Mora-Gil, M., additional, Batista-Liz, J., additional, Prieto-Peña, D., additional, Muñoz Jimenez, A., additional, Ortiz-Sanjuan, F., additional, Romero-Juste, S., additional, Moriano, C., additional, Galíndez-Agirregoikoa, E., additional, Ortego-Centeno, N., additional, Alvarez-Rivas, N., additional, Castañeda, S., additional, and Blanco, R., additional

Published
2024
Full Text
View/download PDF

2. POS1100 EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: CLINICAL SUSPICION RED FLAGS IDENTIFICATION BY A SYSTEMATIC LITERATURE REVIEW AND MULTIDISCIPLINARY EXPERT CONSENSUS

Author

Solans-Laqué, R., primary, Cid, M., additional, Blanco, R., additional, Blanco-Aparicio, M., additional, Garcia-Moguel, I., additional, Arismendi-Nuñez, E., additional, Noblejas Mozo, A., additional, Perez-Grimaldi, F., additional, Labradror-Horrillo, M., additional, Domingo-Rivas, C., additional, Espigol-Frigole, G., additional, Sanchez-Toril, F., additional, Ortiz-Sanjuan, F., additional, Alvaro-Gracia, J. M., additional, and Rúa-Figueroa, Í., additional

Published
2024
Full Text
View/download PDF

3. AB0928 USE OF RITUXIMAB IN SYSTEMIC SCLEROSIS PATIENTS WITH PULMONARY AND DIFFUSE CUTANEOUS INVOLVEMENT. A SERIES OF 15 CASES

Author

Ortiz Sanjuan, F., primary, Grau García, E., additional, Riesco Barcena, C., additional, Charia, H., additional, Huaylla Quispe, A. V., additional, Martínez Cordellat, I., additional, Mas Sanchez, L., additional, Muñoz Martinez, P., additional, Nájera Herranz, C., additional, Negueroles Albuixech, R., additional, Oller Rodríguez, J. E., additional, Ramos Castro, D., additional, Torrat Noves, A. M., additional, Tovar-Sugrañes, E., additional, Vicens Bernabeu, E., additional, Cánovas Olmos, I., additional, Leal Rodriguez, S., additional, Gonzalez Puig, L., additional, Ivorra Cortés, J., additional, and Román Ivorra, J. A., additional

Published
2023
Full Text
View/download PDF

4. TOCILIZUMAB IN LARGE-VESSEL GIANT CELL ARTERITIS AND TAKAYASU ARTERITIS: MULTICENTRIC OBSERVATIONAL COMPARATIVE STUDY

Author

Prieto-Pena D, Loricera J, Castaneda S, Moriano C, Bernabeu P, Vela-Casasempere P, Narvaez J, Aldasoro V, Maiz O, Fernandez-Lopez C, Gonzalez M, Melero R, Villa-Blanco I, Gonzalez-Alvarez B, Solans-Laque R, Callejas-Rubio J, Fernandez-Diaz C, Romero E, Morillo S, Minguez M, Fernandez-Carballido C, De Miguel E, Sanchez-Martin J, Fernandez E, Melchor S, Salgado-Perez E, Bravo B, Romero-Yuste S, Galindez-Agirregoikoa E, Sivera F, Ferraz-Amaro I, Hidalgo C, Romero-Gomez C, Galisteo C, Moya P, Alvarez-Rivas N, Mendizabal J, Gonzalez J, De Dios J, Andreu J, de Pedro I, Revenga M, Valdivieso J, Rosa R, De la Morena I, Fernandez-Llanio N, Labrador E, Roman-Ivorra J, Ortiz-Sanjuan F, Garcia-Valle A, Gallego A, Iniguez C, Garrido-Punal N, De la Torre R, Lopez-Gonzalez R, Collado P, Raya E, Navarro F, Mas A, Ordas C, Boquet M, Feijoo M, Fernandez C, Rua-Figueroa I, Conesa A, Arija S, Gonzalez-Gay M, and Blanco R

Published
2022

5. Treatment With Tofacitinib in Refractory Psoriatic Arthritis: A National Multicenter Study of the First 87 Patients in Clinical Practice

Author

Galíndez-Agirregoikoa E, Prieto-Peña D, Martín-Varillas JL, Joven B, Rusinovich O, Melero-González RB, Ortiz-Sanjuan F, Almodóvar R, Alegre JJ, Martínez Á, Sellas-Fernández A, Méndez L, García-Vicuña R, Atienza-Mateo B, Gorostiza I, González-Gay MÁ, and Blanco R

Subjects
psoriatic arthritis, tofacitinib, real-world data, biologic therapy, clinical practice
Abstract

Objective. Tofacitinib (TOF) is the first Janus kinase (JAK) inhibitor approved for psoriatic arthritis (PsA). It has shown efficacy in patients refractory to anti-tumor necrosis factor-alpha in randomized controlled trials (RCTs). Our aim was to assess efficacy and safety of TOF in clinical practice. Methods. This was an observational, open-label multicenter study of PsA patients treated with TOF due to inefficacy or adverse events of previous therapies. Outcome variables were efficacy, corticosteroid dose-sparing effect, retention rate, and safety. A comparative study of clinical features between our cohort of patients and those from the OPAL Beyond trial was performed. Results. There were 87 patients (28 women/59 men), with a mean age of 52.8 +/- 11.4 years. All patients were refractory to biologic disease-modifying antirheumatic drugs (DMARDs) and/or to conventional synthetic DMARDs plus apremilast. TOF was started at 5 mg twice daily after a mean follow-up of 12.3 +/- 9.3 years from PsA diagnosis. At first month, Disease Activity Score in 28 joints based on erythrocyte sedimentation rate (DAS28-ESR) decreased from median 4.8 (IQR 4.1-5.4) to 3.7 (IQR 2.8-4.7, P < 0.01), Disease Activity Index for Psoriatic Arthritis from median 28 (IQR 18.4-34.1) to 15.5 (IQR 10.1-25.7, P < 0.01), and C-reactive protein from median 1.9 (IQR 0.3-5.0) to 0.5 (IQR 0.1-2.2) mg/dL (P < 0.01). Also, TOF led to a significant reduction in prednisone dose. Mild adverse effects were reported in 21 patients (24.13%), mainly gastrointestinal symptoms. TOF retention rate at Month 6 was 77% (95% CI 65.2-86.3). Patients in clinical practice were older with longer disease duration and received biologic agents more commonly than those in the OPAL Beyond trial. Conclusion. Data from clinical practice confirm that TOF seems to be effective, rapid, and relatively safe in refractory PsA despite clinical differences with patients in RCTs.

Published
2021

6. Tocilizumab in refractory Caucasian Takayasu's arteritis: a multicenter study of 54 patients and literature review

Author

Prieto-Pena D, Bernabeu P, Vela P, Narvaez J, Fernandez-Lopez J, Freire-Gonzalez M, Gonzalez-Alvarez B, Solans-Laque R, Rubio J, Ortego N, Fernandez-Diaz C, Rubio E, Garcia-Morillo S, Minguez M, Fernandez-Carballido C, de Miguel E, Melchor S, Salgado E, Bravo B, Romero-Yuste S, Salvatierra J, Hidalgo C, Manrique S, Romero-Gomez C, Moya P, Alvarez-Rivas N, Mendizabal J, Ortiz-Sanjuan F, de Pedro I, Alonso-Valdivielso J, Perez-Sanchez L, Roldan R, Fernandez-Llanio N, de la Torre R, Suarez S, Cabrera M, Sanchez M, Loricera J, Atienza-Mateo B, Castaneda S, Gonzalez-Gay M, and Blanco R

Subjects
Takayasu's arteritis, cDMARDs, biological therapy, Caucasian, Tocilizumab
Abstract

Objective: To assess the efficacy and safety of tocilizumab (TCZ) in Caucasian patients with refractory Takayasu's arteritis (TAK) in clinical practice. Methods: A multicenter study of Caucasian patients with refractory TAK who received TCZ. The outcome variables were remission, glucocorticoid-sparing effect, improvement in imaging techniques, and adverse events. A comparative study between patients who received TCZ as monotherapy (TCZ(MONO)) and combined with conventional disease modifying anti-rheumatic drugs (cDMARDs) (TCZ(COMBO)) was performed. Results: The study comprised 54 patients (46 women/8 men) with a median [interquartile range (IQR)] age of 42.0 (32.5-50.5) years. TCZ was started after a median (IQR) of 12.0 (3.0-31.5) months since TAK diagnosis. Remission was achieved in 12/54 (22.2%), 19/49 (38.8%), 23/44 (52.3%), and 27/36 (75%) patients at 1, 3, 6, and 12 months, respectively. The prednisone dose was reduced from 30.0 mg/day (12.5-50.0) to 5.0 (0.0-5.6) mg/day at 12 months. An improvement in imaging findings was reported in 28 (73.7%) patients after a median (IQR) of 9.0 (6.0-14.0) months. Twenty-three (42.6%) patients were on TCZ(MONO) and 31 (57.4%) on TCZ(COMBO): MTX (n = 28), cyclosporine A (n = 2), azathioprine (n = 1). Patients on TCZ(COMBO) were younger [38.0 (27.0-46.0) versus 45.0 (38.0-57.0)] years; difference (diff) [95% confidence interval (CI) = -7.0 (-17.9, -0.56] with a trend to longer TAK duration [21.0 (6.0-38.0) versus 6.0 (1.0-23.0)] months; diff 95% CI = 15 (-8.9, 35.5), and higher c-reactive protein [2.4 (0.7-5.6) versus 1.3 (0.3-3.3)] mg/dl; diff 95% CI = 1.1 (-0.26, 2.99). Despite these differences, similar outcomes were observed in both groups (log rank p = 0.862). Relevant adverse events were reported in six (11.1%) patients, but only three developed severe events that required TCZ withdrawal. Conclusion: TCZ in monotherapy, or combined with cDMARDs, is effective and safe in patients with refractory TAK of Caucasian origin.

Published
2021

7. Diagnosis of Giant Cell Arteritis in Spain: Data from the ARTESER Registry

Author

De Miguel, E, Sanchez-Costa, JT, Narvaez, J, Gonzalez-Gay, M, Garrido-Punal, N, Estrada-Alarcon, PV, Hernandez-Rodriguez, I, Fernandez-Fernandez, E, Silva-Diaz, MT, Valero-Jaimes, JA, Gonzalez-Fernandez, I, Sanchez, J, Lluch, J, Galindez-Agirregoikoa, E, Mendizabal-Mateos, J, Rodriguez, LR, Garcia, JL, Munoz, A, Castaneda, S, Moya, P, Moran-Alvarez, P, Navarro-Angeles, VA, Calvet-Fontova, J, Casafont, I, Ortiz-Sanjuan, F, Labrada-Arrabal, S, Campos-Fernandez, C, Alcalde-Villar, M, Juan-Mas, A, and Blanco, R

Published
2021

9. POS1365 ANNALYSIS OF PRO-INFLAMMATORY BIOMARKERS IN A POLYMYALGIA RHEUMATICA COHORT DURING THE ACUTE ONSET OF THE DISEASE

Author

Ortiz Sanjuan, F. M., primary, Grau García, E., additional, Riesco Barcena, C., additional, Huaylla Quispe, A. V., additional, Pávez Perales, C., additional, Leal Rodriguez, S., additional, De la Rubia Navarro, M., additional, Martínez Cordellat, I., additional, Nájera Herranz, C., additional, Negueroles Albuixech, R., additional, Oller Rodríguez, J. E., additional, Vicens Bernabeu, E., additional, Alcañiz Escandell, C., additional, Cánovas Olmos, I., additional, Chalmeta Verdejo, I., additional, Fragío Gil, J. J., additional, Gonzalez Puig, L., additional, Ivorra Cortés, J., additional, and Román Ivorra, J. A., additional

Published
2021
Full Text
View/download PDF

10. POS1157 CONCORDANCE BETWEEN THE QUANTIFERON-TB GOLD IN-TUBE AND TUBERCULIN TEST FOR THE DIAGNOSIS OF LATENT TUBERCULOSIS INFECTION IN PATIENTS WITH RHEUMATIC DISEASES

Author

Pávez Perales, C., primary, Quiles Roger, A., additional, Grau García, E., additional, De la Rubia Navarro, M., additional, Leal Rodriguez, S., additional, Gonzalez Mazario, R., additional, Fragío Gil, J. J., additional, Alcañiz Escandell, C., additional, Ivorra Cortés, J., additional, Chalmeta Verdejo, I., additional, Gonzalez Puig, L., additional, Martínez Cordellat, I., additional, Negueroles Albuixech, R., additional, Ortiz Sanjuan, F. M., additional, Oller Rodríguez, J. E., additional, Vicens Bernabeu, E., additional, Nájera Herranz, C., additional, Cánovas Olmos, I., additional, and Román Ivorra, J. A., additional

Published
2021
Full Text
View/download PDF

11. POS0595 ABATACEPT IN USUAL AND IN NON-SPECIFIC INTERSTITIAL PNEUMONIA ASSOCIATED TO RHEUMATOID ARTHRITIS. NATIONAL MULTICENTER STUDY OF 190 PATIENTS

Author

Atienza-Mateo, B., primary, Fernández-Díaz, C., additional, Castañeda, S., additional, Melero, R., additional, Ortiz Sanjuan, F., additional, Casafont-Solé, I., additional, Rodriguez-García, S. C., additional, Ferraz-Amaro, I., additional, González-Gay, M. A., additional, and Blanco, R., additional

Published
2021
Full Text
View/download PDF

12. AB0366 TOCILIZUMAB FOR TAKAYASU ARTERITIS: MULTICENTER STUDY OF 54 WHITE PATIENTS

Author

Prieto-Peña, D., primary, Bernabéu, P., additional, Vela-Casasempere, P., additional, Narváez, J., additional, Fernández-López, C., additional, Freire González, M., additional, González-Alvarez, B., additional, Solans-Laqué, R., additional, Callejas-Rubio, J. L., additional, Ortego, N., additional, Fernández-Díaz, C., additional, Rubio Romero, E., additional, García Morillo, S., additional, Minguez, M., additional, Fernández-Carballido, C., additional, De Miguel, E., additional, Melchor, S., additional, Salgado-Pérez, E., additional, Bravo, B., additional, Romero-Yuste, S., additional, Salvatierra, J., additional, Hidalgo, C., additional, Manrique Arija, S., additional, Romero-Gómez, C., additional, Moya, P., additional, Alvarez-Rivas, N., additional, Mendizabal, J., additional, Ortiz Sanjuan, F. M., additional, Pérez de Pedro, I., additional, Alonso Valdivieso, J. L., additional, Laura, P. S., additional, Rosa, R. M., additional, Fernández-Llanio, N., additional, Gómez de la Torre, R., additional, Suarez, S., additional, Montesa, M. J., additional, Delgado Sanchez, M., additional, Loricera, J., additional, Atienza-Mateo, B., additional, Castañeda, S., additional, González-Gay, M. A., additional, and Blanco, R., additional

Published
2021
Full Text
View/download PDF

13. AB0502 HEALTH-RELATED QUALITY OF LIFE MEASURES IN SPONDYLOARTHROPATY PATIENTS UNDER BIOLOGICAL THERAPIES IN REAL LIFE

Author

Grau García, E., primary, De la Rubia Navarro, M., additional, Pávez Perales, C., additional, Leal Rodriguez, S., additional, Riesco Barcena, C., additional, Huaylla Quispe, A. V., additional, Vicens Bernabeu, E., additional, Negueroles Albuixech, R., additional, Ivorra Cortés, J., additional, Ortiz Sanjuan, F. M., additional, Martínez Cordellat, I., additional, Chalmeta Verdejo, I., additional, Fragío Gil, J. J., additional, Gonzalez Puig, L., additional, Oller Rodríguez, J. E., additional, Alcañiz Escandell, C., additional, Cánovas Olmos, I., additional, Nájera Herranz, C., additional, Cañada Martinez, A. J., additional, and Román Ivorra, J. A., additional

Published
2021
Full Text
View/download PDF

14. POS0167 SECONDARY PREVENTION OF VERTEBRAL FRACTURES IN REAL PRACTICE

Author

Oller Rodríguez, J. E., primary, Grau García, E., additional, Leal Rodriguez, S., additional, Acosta, M. E., additional, Riesco Barcena, C., additional, Huaylla Quispe, A. V., additional, Pávez Perales, C., additional, De la Rubia Navarro, M., additional, Martínez Cordellat, I., additional, Nájera Herranz, C., additional, Negueroles Albuixech, R., additional, Ortiz Sanjuan, F. M., additional, Vicens Bernabeu, E., additional, Alcañiz Escandell, C., additional, Cánovas Olmos, I., additional, Chalmeta Verdejo, I., additional, Fragío Gil, J. J., additional, Gonzalez Puig, L., additional, Ivorra Cortés, J., additional, and Román Ivorra, J. A., additional

Published
2021
Full Text
View/download PDF

15. AB1066 EFFICACY AND SAFETY OF APREMILAST IN BEHÇET DISEASE PATIENTS

Author

Vicens Bernabeu, E., primary, Grau García, E., additional, Alcañiz Escandell, C., additional, Ortiz Sanjuan, F. M., additional, Gonzalez Mazario, R., additional, De la Rubia Navarro, M., additional, Pávez Perales, C., additional, Leal Rodriguez, S., additional, Ivorra Cortés, J., additional, Gonzalez Puig, L., additional, Chalmeta Verdejo, I., additional, Negueroles Albuixech, R., additional, Martínez Cordellat, I., additional, Fragio-Gil, J. J., additional, Oller Rodríguez, J. E., additional, Nájera Herranz, C., additional, Cánovas Olmos, I., additional, and Román Ivorra, J. A., additional

Published
2020
Full Text
View/download PDF

16. AB0165 THE ROLE OF CXCL4, CXCL8 AND GDF-15 IN SYSTEMIC SCLEROSIS

Author

Oller Rodriguez, J. E., primary, Grau García, E., additional, Gonzalez Mazario, R., additional, De la Rubia Navarro, M., additional, Pávez Perales, C., additional, Leal Rodriguez, S., additional, Martínez Cordellat, I., additional, Ortiz Sanjuan, F. M., additional, Vicens Bernabeu, E., additional, Negueroles Albuixech, R., additional, Chalmeta Verdejo, I., additional, Alcañiz Escandell, C., additional, Fragio-Gil, J. J., additional, Cánovas Olmos, I., additional, Nájera Herranz, C., additional, Gonzalez Puig, L., additional, Ivorra Cortés, J., additional, Hervás Marín, D., additional, and Román Ivorra, J. A., additional

Published
2020
Full Text
View/download PDF

17. AB1048 RHUPUS SYNDROME IN A TERTIARY HOSPITAL

Author

Martínez Cordellat, I., primary, Gonzalez Mazario, R., additional, De la Rubia Navarro, M., additional, Pávez Perales, C., additional, Leal Rodriguez, S., additional, Ivorra Cortés, J., additional, Chalmeta Verdejo, I., additional, Grau García, E., additional, Alcañiz Escandell, C., additional, Fragio-Gil, J. J., additional, Gonzalez Puig, L., additional, Negueroles Albuixech, R., additional, Oller Rodríguez, J. E., additional, Ortiz Sanjuan, F. M., additional, Vicens Bernabeu, E., additional, Nájera Herranz, C., additional, Cánovas Olmos, I., additional, and Román Ivorra, J. A., additional

Published
2020
Full Text
View/download PDF

18. SAT0077 CARDIOVASCULAR RISK ASSESSMENT WITH CAROTID ULTRASONOGRAPHY IN ADDITION TO THE TRADITIONAL CARDIOVASCULAR RISK FACTORS IN RHEUMATOID ARTHRITIS PATIENTS: A CASE CONTROL STUDY

Author

Gonzalez Mazario, R., primary, Fragio-Gil, J. J., additional, Martinez Calabuig, P., additional, Grau García, E., additional, De la Rubia Navarro, M., additional, Pávez Perales, C., additional, Leal Rodriguez, S., additional, Martínez Cordellat, I., additional, Ivorra Cortés, J., additional, Negueroles Albuixech, R., additional, Oller Rodríguez, J. E., additional, Gonzalez Puig, L., additional, Alcañiz Escandell, C., additional, Chalmeta Verdejo, I., additional, Ortiz Sanjuan, F. M., additional, Vicens Bernabeu, E., additional, Cánovas Olmos, I., additional, Nájera Herranz, C., additional, and Román Ivorra, J. A., additional

Published
2020
Full Text
View/download PDF

19. SAT0270 TOCILIZUMAB IN REFRACTORY TAKAYASU ARTERITIS. OPEN-LABEL NATIONAL MULTICENTER STUDY OF 53 PATIENTS OF CLINICAL PRACTICE

Author

Prieto-Peña, D., primary, Calderón-Goercke, M., additional, Bernabéu, P., additional, Vela-Casasempere, P., additional, Narváez, J., additional, Fernández-López, C., additional, Freire González, M., additional, González-Alvarez, B., additional, Solans-Laqué, R., additional, Callejas-Rubio, J. L., additional, Ortego, N., additional, Fernández-Díaz, C., additional, Rubio Romero, E., additional, García Morillo, S., additional, Minguez, M., additional, Fernández-Carballido, C., additional, De Miguel, E., additional, Melchor, S., additional, Salgado-Pérez, E., additional, Bravo, B., additional, Romero-Yuste, S., additional, Salvatierra, J., additional, Hidalgo, C., additional, Manrique Arija, S., additional, Romero-Gómez, C., additional, Moya, P., additional, Alvarez-Rivas, N., additional, Mendizabal, J., additional, Ortiz Sanjuan, F. M., additional, Pérez de Pedro, I., additional, Loricera, J., additional, Castañeda, S., additional, González-Gay, M. A., additional, and Blanco, R., additional

Published
2020
Full Text
View/download PDF

20. FRI0437 CT GUIDED NEEDLE BIOPSY IN VERTEBRAL OSTEOMYELITIS: RELIABILITY ANALYSIS AND STUDY OF WHICH FACTORS COULD INFLUENCE ON THE RESULT

Author

Fragio-Gil, J. J., primary, Gonzalez Mazario, R., additional, Grau García, E., additional, De la Rubia Navarro, M., additional, Pávez Perales, C., additional, Leal Rodriguez, S., additional, Ivorra Cortés, J., additional, Gonzalez Puig, L., additional, Negueroles Albuixech, R., additional, Martínez Cordellat, I., additional, Chalmeta Verdejo, I., additional, Oller Rodríguez, J. E., additional, Alcañiz Escandell, C., additional, Vicens Bernabeu, E., additional, Ortiz Sanjuan, F. M., additional, Nájera Herranz, C., additional, Cánovas Olmos, I., additional, Cañada Martinez, A. J., additional, Salavert Lleti, M., additional, and Román Ivorra, J. A., additional

Published
2020
Full Text
View/download PDF

21. AB0597 PULMONARY FUNCTION IN PATIENTS DIAGNOSED OF EARLY SYSTEMIC SCLEROSIS: A NEW TOOL FOR SYSTEMIC SCLEROSIS CLASIFFICATION?

Author

Ortiz Sanjuan, F. M., primary, Pávez Perales, C., additional, Vicens Bernabeu, E., additional, Alcañiz Escandell, C., additional, Cánovas Olmos, I., additional, Chalmeta Verdejo, I., additional, De la Rubia Navarro, M., additional, Gonzalez Mazario, R., additional, Gonzalez Puig, L., additional, Grau García, E., additional, Ivorra Cortés, J., additional, Leal Rodriguez, S., additional, Martínez Cordellat, I., additional, Nájera Herranz, C., additional, Negueroles Albuixech, R., additional, Oller Rodríguez, J. E., additional, and Román Ivorra, J. A., additional

Published
2020
Full Text
View/download PDF

22. FRI0124 EFFICACY AND SAFETY OF BARICITINIB AND TOFACITINIB IN RHEUMATOID ARTHRITIS: DATA FROM REAL-WORLD

Author

Gonzalez Mazario, R., primary, Fragio-Gil, J. J., additional, Grau García, E., additional, De la Rubia Navarro, M., additional, Pávez Perales, C., additional, Leal Rodriguez, S., additional, Ivorra Cortés, J., additional, Negueroles Albuixech, R., additional, Gonzalez Puig, L., additional, Oller Rodríguez, J. E., additional, Alcañiz Escandell, C., additional, Vicens Bernabeu, E., additional, Chalmeta Verdejo, I., additional, Martínez Cordellat, I., additional, Ortiz Sanjuan, F. M., additional, Nájera Herranz, C., additional, Cánovas Olmos, I., additional, Cañada Martinez, A. J., additional, and Román Ivorra, J. A., additional

Published
2020
Full Text
View/download PDF

23. Abatacept in Rheumatoid Arthritis with Interstitial Lung Disease: A Retrospective Multicenter Study of 263 Patients

Author

Fernandez-Diaz, C, Melero, R, Loricera, J, Castaneda, S, Ortiz-Sanjuan, F, Casafont-Sole, I, Carrasco-Cubero, C, Juan-Mas, A, Almodovar-Gonzalez, R, Rodriguez-Garcia, S, Castellanos, R, Maiz-Alonso, O, Aguilera-Cros, C, Cabezas-Rodriguez, I, Cervantes, EC, Moreno, M, Arboleya, L, Montagut, C, Carreira, P, Ojeda-Garcia, C, Bonilla, G, Perez-Sandoval, T, Vela, P, Andreu, JL, Romero-Yuste, S, Urruticoechea-Arana, A, Salgado-Perez, E, Hidalgo, C, Narvaez, J, Raya, E, Moreno-Ramos, MJ, Morales-Garrido, P, Perez-Alba, L, Fernandez-Lopez, C, Villa, I, Alvarez-Rivas, N, Blanco-Madrigal, JM, Jimenez-Aberasturi, JR, Perez-Linaza, A, Del-val-del-amo, N, Fernandez, S, Garciavalle, A, Peralta-Gines, CA, Garcia-Aparicio, A, Exposito-perez, L, Mena-Vazquez, N, Lopez-Sanchez, R, Garcia-magallon, B, Gonzalez-Gay, MA, and Blanco, R

Published
2019

24. Optimization of Tocilizumab Therapy in Giant Cell Arteritis: A Multicenter Real Life Study of 134 Patients

Author

Calderon-Goercke, M, Loricera, J, Prieto-Pena, D, Castaneda, S, Caceres, VA, Villa, I, Humbria, A, Moriano, C, Romero-Yuste, S, Narvaez, J, Gomez-Arango, C, Pampin, EP, Melero, R, Becerra-Fernandez, E, Revenga, M, Alvarez-Rivas, N, Galisteo, C, Sivera, F, Olive-Marques, A, del Buergo, MA, Marena-Rojas, L, Fernandez-Lopez, C, Navarro, F, Raya, E, Galindez-Agirregoikoa, E, Arca, B, Solans-Laque, R, Conesa, A, Hidalgo, C, Vazquez, C, Roman-Ivorra, JA, Lluch, P, Manrique, S, Vela, P, de Miguel, E, Torres-Martin, C, Nieto, JC, Ordas-Calvo, C, Salgado-Perez, E, Luna-Gomez, C, De Miera, FJTS, Fernandez-Llanio, N, Garcia, A, Larena, C, Varela-Garcia, M, Aurrecoechea, E, Ortiz-Sanjuan, F, Hernandez, JL, Gonzalez-Gay, MA, and Blanco, R

Published
2019

25. Tocilizumab in Giant Cell Arteritis: The Safest and Most Effective Initial Dose of Prednisone

Author

Calderon-Goercke, M, Loricera, J, Prieto-Pena, D, Castaneda, S, Caceres, VA, Villa, I, Humbria, A, Moriano, C, Romero-Yuste, S, Narvaez, J, Gomez-Arango, C, Pampin, EP, Melero, R, Becerra-Fernandez, E, Revenga, M, Alvarez-Rivas, N, Galisteo, C, Sivera, F, Olive-Marques, A, del Buergo, MA, Marena-Rojas, L, Fernandez-Lopez, C, Navarro, F, Raya, E, Galindez-Agirregoikoa, E, Arca, B, Solans-Laque, R, Conesa, A, Hidalgo, C, Vazquez, C, Roman-Ivorra, JA, Lluch, P, Manrique, S, Vela, P, de Miguel, E, Torres-Martin, C, Nieto, JC, Ordas-Calvo, C, Salgado-Perez, E, Luna-Gomez, C, De Miera, FJTS, Fernandez-Llanio, N, Garcia, A, Aurrecoechea, E, Ortego, N, Ortiz-Sanjuan, F, Corteguera, M, Hernandez, JL, Gonzalez-Gay, MA, and Blanco, R

Published
2019

26. Tocilizumab in Giant Cell Arteritis: Route of Administration: Intravenous or Subcutaneous

Author

Calderon-Goercke, M, Loricera, J, Prieto-Pena, D, Castaneda, S, Caceres, VA, Villa, I, Humbria, A, Moriano, C, Romero-Yuste, S, Narvaez, J, Gomez-Arango, C, Pampin, EP, Melero, R, Becerra-Fernandez, E, Revenga, M, Alvarez-Rivas, N, Galisteo, C, Sivera, F, Olive-Marques, A, del Buergo, MA, Marena-Rojas, L, Fernandez-Lopez, C, Navarro, F, Raya, E, Galindez-Agirregoikoa, E, Arca, B, Solans-Laque, R, Conesa, A, Hidalgo, C, Vazquez, C, Roman-Ivorra, JA, Lluch, P, Manrique, S, Vela, P, de Miguel, E, Torres-Martin, C, Nieto, JC, Ordas-Calvo, C, Salgado-Perez, E, Luna-Gomez, C, De Miera, FJTS, Fernandez-Llanio, N, Garcia, A, Larena, C, Varela-Garcia, M, Aurrecoechea, E, Ortiz-Sanjuan, F, Hernandez, JL, Gonzalez-Gay, MA, and Blanco, R

Published
2019

27. Apremilast in Combination vs Monotherapy for Refractory Oral And/or Genital Ulcers in Behcet's Disease: National Multicenter Study of 51 Cases

Author

Atienza-Mateo B, Calderon-Goercke M, Prieto-Pena D, Gonzalez-Mazon I, Sanchez-Bilbao L, Martin-Varillas J, Loricera J, Rio V, Grana J, Espinosa G, Moriano C, Perez-Sandoval T, Martin-Martinez M, Diez E, Garcia-Armario M, Martinez E, Castellvi I, Alvarado P, Sivera F, Calvo-Alen J, de la Morena I, Ortiz-Sanjuan F, Roman-Ivorra J, Perez-Gomez A, Heredia S, Olive-Marques A, Prior-Espanol A, Diez C, Alegre-Sancho J, Ybanez A, Martinez-Ferrer A, Narvaez J, Figeras I, Turrion A, Romero-Yuste S, Trenor P, Ojeda S, Gonzalez-Gay M, and Blanco R

Published
2019

28. UTILITY OF APREMILAST IN REFRACTORY ORAL AND/OR GENITAL ULCERS IN BEHCET'S DISEASE

Author

Atienza-Mateo B, Loricera J, Garcia-Armario M, Castellvi I, Sivera F, Grana J, Calvo-Alen J, de la Morena I, Ortiz-Sanjuan F, Roman-Ivorra J, Perez-Gomez A, Heredia S, Diez C, Alegre J, Moriano C, Diez E, Perez T, Martin M, Ybanez A, Narvaez J, Turrion A, Romero-Yuste S, Dominguez-Casas L, Vegas-Revenga N, Martin-Varillas J, Hernandez J, Gonzalez-Vela C, Gonzalez-Gay M, and Blanco R

Published
2018

29. THU0186 Rheumatoid arthritis and interstitial lung disease. multicentric retrospective study of 118 patients treated with biological no anti tnf

Author

Fernández-Díaz, C., primary, Castañeda, S., additional, Garcia-Magallon, B., additional, Narvaez-García, J., additional, Retuerto, M., additional, Perez-Sandoval, T., additional, Martin-Lopez, M., additional, Rubio-muñoz, P., additional, Carrasco-Cubero, M., additional, Reina-Sainz, D., additional, Urruticoechea, A., additional, Ojeda-Garcia, C., additional, Rodriguez-Muguruza, S., additional, Carreira, P., additional, Belmar-Vega, L., additional, Cervantes, E., additional, Robles-flores, B., additional, Arboleya, L., additional, Bonilla, G., additional, Hernandez-Rodriguez, I., additional, Maiz-Alonso, O., additional, Palma, D., additional, Delgado, C., additional, Expósito-Molinero, R., additional, Ortiz-Sanjuan, F., additional, Ruibal-Escribano, A., additional, Ordoñez, S., additional, Moreno, M., additional, Villa blanco, I., additional, Fito, C., additional, Blanco-Madrigal, J., additional, Bernal, J., additional, Romero, S., additional, Mena-Vazquez, N., additional, Lopez-corbeto, M., additional, Mas, T.J., additional, Vazqzez, T.R., additional, Gonzalez-Gay, M.A., additional, Blanco, R., additional, Macarena, H., additional, and Bernal, Sevill J., additional

Published
2018
Full Text
View/download PDF

31. USE OF RITUXIMAB IN SYSTEMIC SCLEROSIS PATIENTS WITH PULMONARY AND DIFFUSE CUTANEOUS INVOLVEMENT. A SERIES OF 15 CASES.

Author

Ortiz Sanjuan, F., Grau García, E., Riesco Barcena, C., Charia, H., Huaylla Quispe, A. V., Martínez Cordellat, I., Mas Sanchez, L., Muñoz Martinez, P., Nájera Herranz, C., Negueroles Albuixech, R., Oller Rodríguez, J. E., Ramos Castro, D., Torrat Noves, A. M., Tovar-Sugrañes, E., Vicens Bernabeu, E., Cánovas Olmos, I., Leal Rodriguez, S., Gonzalez Puig, L., Ivorra Cortés, J., and Román Ivorra, J. A.

Published
2023
Full Text
View/download PDF

32. Efficacy of Tocilizumab in Conventional Treatment-Refractory Adult-Onset Still's Disease

Author

Ortiz-Sanjuan, F, Blanco, R, Calvo-Rio, V, Narvaez, J, Romero, ER, Olive, A, Castaneda, S, Flores, AG, Hernandez, MV, Mata, C, Vilamajo, IR, Giraldo, WAS, Caracuel, MA, Freire, M, Arango, CG, Llobet, J, Arija, SM, Marras, C, Moll-Tuduri, C, Plasencia-Rodriguez, C, Rosello, R, Urruticoechea, A, Velloso-Feijoo, ML, del Blanco, J, Gonzalez-Vela, MC, Rueda-Gotor, J, Pina, T, Loricera, J, and Gonzalez-Gay, MA

Abstract

Objective. Adult-onset Still's disease (AOSD) is frequently refractory to standard therapy. Tocilizumab (TCZ) has demonstrated efficacy in single cases and in small series of patients with AOSD. The aim of this multicenter study was to assess the efficacy of TCZ in patients with AOSD refractory to conventional treatment. Methods. This was a retrospective open-label study of TCZ treatment in 34 patients with AOSD who had experienced an inadequate response to corticosteroids and at least 1 standard synthetic immunosuppressive drug and also, in many cases, biologic agents. Results. The mean +/- SD age of the patients (8 men and 26 women) was 38.7 +/- 16.1 years. The median duration of AOSD before TCZ was initiated was 4.2 years (interquartile range [IQR] 1-9 years). The initial dosages of intravenous TCZ were 8 mg/kg every 4 weeks in 22 patients, 4 mg/kg every 4 weeks in 2 patients, and 8 mg/kg every 2 weeks in 10 patients. TCZ treatment resulted in rapid and maintained improvement in both clinical and laboratory parameters. After 1 year of TCZ therapy, the incidence of joint manifestations had decreased from 97.1% at baseline to 32.4%, the incidence of both cutaneous manifestations and fever had decreased from 58.8% to 5.9%, and the incidence of lymphadenopathy had decreased from 29.4% to 0%. A dramatic reduction in laboratory markers of inflammation, including the C-reactive protein level, the erythrocyte sedimentation rate, and the ferritin level, was achieved. The median dosage of prednisone was also reduced, from 13.8 mg/day (IQR 5-45) at the initiation of TCZ to 2.5 mg/day (IQR 0-30) at 12 months. After a median followup of 19 months (IQR 12-31 months), only 2 patients required permanent discontinuation of TCZ therapy because of severe infections. Conclusion. TCZ treatment was associated with rapid and maintained clinical and laboratory improvement in patients with AOSD refractory to standard treatment. However, joint manifestations seem to be more refractory to treatment compared with systemic manifestations.

Published
2014

33. SAT0525 Tocilizumab Compared with Anakinra in Refractory Adult-Onset Still's Disease. Multicenter Study of 75 Patients

Author

Palmou, N., primary, Calvo-Río, V., additional, Blanco, R., additional, Hernández, J.L., additional, Ortiz-Sanjuan, F., additional, Olivé, A., additional, Riveros, A., additional, Castañeda, S., additional, Narváez, F.J., additional, Velloso-Feijoo, M.L., additional, Hernández, M.V., additional, Sifuentes Giraldo, W.A., additional, Maiz Alonso, O., additional, Rubio Romero, E., additional, Mata, C., additional, Gallego Flores, A., additional, del Blanco-Barnusell, J., additional, Gόmez-Arango, C., additional, Ordόñez, M.D.C., additional, Caracuel, M.A., additional, Velloso Feijoo, M.L., additional, Jiménez-Moleόn, I., additional, Bernal, J.A., additional, and González-Gay, M.A., additional

Published
2015
Full Text
View/download PDF

34. Single-organ cutaneous small-vessel vasculitis according to the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides: a study of 60 patients from a series of 766 cutaneous vasculitis cases

Author

Loricera, J., primary, Blanco, R., additional, Ortiz-Sanjuan, F., additional, Hernandez, J. L., additional, Pina, T., additional, Gonzalez-Vela, M. C., additional, Calvo-Rio, V., additional, Rueda-Gotor, J., additional, Alvarez, L., additional, Gonzalez-Lopez, M. A., additional, Marcellan, M., additional, and Gonzalez-Gay, M. A., additional

Published
2014
Full Text
View/download PDF

35. Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis-multicentre study of 263 Caucasian patients.

Author

Fernández-Díaz C, Atienza-Mateo B, Castañeda S, Melero-Gonzalez RB, Ortiz-SanJuan F, Loricera J, Casafont-Solé I, Rodríguez-García S, Aguilera-Cros C, Villa-Blanco I, Raya-Alvarez E, Ojeda-García C, Bonilla G, López-Robles A, Arboleya L, Narváez J, Cervantes E, Maiz O, Alvarez-Rivas MN, Cabezas I, Salgado E, Hidalgo-Calleja C, Fernández S, Fernández JC, Ferraz-Amaro I, González-Gay MA, and Blanco R

Subjects
Aged, Antirheumatic Agents therapeutic use, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Retrospective Studies, Abatacept therapeutic use, Arthritis, Rheumatoid drug therapy, Lung Diseases, Interstitial drug therapy, Methotrexate therapeutic use
Abstract

Objective: To assess the efficacy and safety of abatacept (ABA) in monotherapy (ABAMONO) vs combined ABA [ABA plus MTX (ABAMTX) or ABA plus non-MTX conventional synthetic DMARDs (csDMARDs) (ABANON-MTX)] in RA patients with interstitial lung disease (ILD) (RA-ILD)., Methods: This was a restrospective multicentre study of RA-ILD Caucasian patients treated with ABA. We analysed in the three groups (ABAMONO, ABAMTX, ABANON-MTX) the following outcome variables: (i) dyspnoea; (ii) forced vital capacity (FVC) and diffusion capacity of the lung for the carbon monoxide (DLCO); (iii) chest high-resolution CT (HRCT); (iv) DAS28-ESR; (v) CS-sparing effect; and (vi) ABA retention and side-effects. Differences between basal and final follow-up were evaluated. Multivariable linear regression was used to assess the differences between the three groups., Results: We studied 263 RA-ILD patients (mean ± s.d. age 64.6 ± 10 years) [ABAMONO (n = 111), ABAMTX (n = 46) and ABANON-MTX (n = 106)]. At baseline, ABAMONO patients were older (67 ± 10 years) and took higher prednisone dose [10 (interquartile range 5-15) mg/day]. At that time, there were no statistically significant differences in sex, seropositivity, ILD patterns, FVC and DLCO, or disease duration. Following treatment, in all groups, most patients experienced stabilization or improvement in FVC, DLCO, dyspnoea and chest HRCT as well as improvement in DAS28-ESR. A statistically significant difference between basal and final follow-up was only found in CS-sparing effect in the group on combined ABA (ABAMTX or ABANON-MTX). However, in the multivariable analysis, there were no differences in any outcome variables between the three groups., Conclusion: In Caucasian individuals with RA-ILD, ABA in monotherapy or combined with MTX or with other conventional-DMARDs seems to be equally effective and safe. However, a CS-sparing effect is only observed with combined ABA., (© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results